A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (NCT07218926)
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (124 Sites)
Showing the first 25 of 124 sites.
- GSK Investigational Site — Phoenix, Arizona
- GSK Investigational Site — La Jolla, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — San Francisco, California
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — Tampa, Florida
- GSK Investigational Site — Iowa City, Iowa
- GSK Investigational Site — Overland Park, Kansas
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Ann Arbor, Michigan
- GSK Investigational Site — Rochester, Minnesota
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — Omaha, Nebraska
- GSK Investigational Site — Lake Success, New York
- GSK Investigational Site — New York, New York
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Rochester, New York
- GSK Investigational Site — Durham, North Carolina
- GSK Investigational Site — Columbus, Ohio
- GSK Investigational Site — Portland, Oregon
- GSK Investigational Site — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Neoplasms
- Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei — Houston, Texas
- Monopolar Current Cutting Knife vs Bipolar RFA Knife — Houston, Texas
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors — Miami, Florida
- Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer — Duarte, California
- Feasibility and Prospective Study of a Dynamic Traction Device for Use During ESD — Houston, Texas
- The Canopy Cancer Collective Clinical Registry Protocol — San Diego, California
Explore by condition: All Gastrointestinal Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.